Liposomal NAD+ Ingredients: Market Growth, Bioavailability Innovation, and B2B Formulation Trends

For procurement managers and brand owners evaluating next-generation longevity ingredients, the NAD+ supplement market is undergoing a fundamental transformation-one driven not by new molecules alone, but by liposomal NAD+ powder and advanced delivery technologies that address the bioavailability limitations of conventional oral NAD+ formulations.

This article focuses primarily on the NAD+ dietary supplement finished product market (booster segment), while broader ecosystem figures are referenced for context. The global NAD+ booster market was valued at approximately US$593 million in 2025 and is forecast to reach US$1.54 billion by 2032, at a CAGR of 14.8%. Yet within this expanding category, liposomal delivery is emerging as a key differentiator, reshaping how brands formulate, position, and commercialize NAD+ products for the growing longevity market.

• The global NAD+ booster market is projected to grow from $593 million in 2025 to $1.54 billion by 2032 at a CAGR of 14.8%.
• NAD+ precursor supplements generated an estimated $346 million in sales in 2025.
• Human clinical studies have reported that liposomal NAD+ formulations may enhance bioavailability compared to standard NAD+, with a 1.52× increase in bioavailability observed in a clinical study.

For B2B buyers, key evaluation criteria include encapsulation efficiency, particle size distribution, stability data, and batch-specific analytical documentation.

Before examining growth projections, it is essential to clarify the market segments referenced throughout this analysis.

The NAD+ booster market-defined as finished dietary supplement products designed to elevate NAD+ levels-was valued at approximately US$593 million in 2025 and is forecast to reach US$1.54 billion by 2032, at a CAGR of 14.8%. This represents the most relevant segment for B2B ingredient buyers formulating finished supplement products.

The broader NAD+ products ecosystem-encompassing IV therapies, research reagents, pharmaceutical applications, and related products-was valued at $3.45 billion in 2024 and is expected to reach $12.18 billion by 2033, growing at a CAGR of 15.1%. Within this broader ecosystem, the U.S. NAD+ products market alone generated $622.2 million in revenue in 2024.

NAD+ precursor supplements (NMN and NR) generated an estimated $346 million in sales in 2025, with projections of $447 million in 2026 and $557 million by 2027. NMN is projected to capture 45% of the NAD+ precursor market share in 2025, driven by strong clinical data and consumer trust.

The Asia Pacific NAD+ products market is expected to reach $8.18 billion by 2033, growing at a CAGR of 17%, reflecting significant regional growth opportunities.

What this means for procurement: The sustained growth across multiple NAD+ market segments reflects increasing industrial confidence in NAD+ supplementation as a category. The premium segment, including liposomal formulations, is capturing an expanding share of this growth.

The NAD+ supplement market is experiencing robust growth across multiple segments:

• The NAD+ booster market is projected to grow at a CAGR of 14.8% from 2025 to 2032.
• The broader NAD+ products market grew from $5.59 billion in 2025 to $6.48 billion in 2026 at a CAGR of 16.1%.
• NAD+ precursor supplements are expected to grow from $346 million in 2025 to $557 million by 2027.
• The liposomal supplements market is projected at $771.76 million in 2025 and expected to reach $1.52 billion by 2033, growing at a CAGR of 8.84%.
• Longevity is dominating supplement innovation in Europe, with NAD+ inclusion identified as a top strategy for 2026.
• The U.S. NAD+ products market generated $622.2 million in revenue in 2024 and is expected to reach $1.77 billion by 2033. The global NAD+ and longevity nutraceutical supplement market was valued at $3.4 billion in 2025.

What this means for procurement: The sustained double-digit growth across multiple NAD+ market segments reflects increasing industrial confidence in NAD+ supplementation as a category. The premium segment, including liposomal formulations, is capturing an expanding share of this growth.

The NAD+ supplement market is increasingly defined by delivery technology rather than ingredient selection alone. Among emerging solutions, liposomal delivery has become one of the most discussed approaches in supplement formulation.

The bioavailability challenge. Conventional oral NAD+ supplements face well-documented bioavailability limitations. Most oral NAD+ is not directly bioavailable and is often metabolized into precursors such as nicotinamide before systemic uptake. This has historically constrained the effectiveness of oral NAD+ supplementation and limited brand claims.

The liposomal approach. Liposomal encapsulation packages NAD+ within phospholipid bilayers, creating microscopic vesicles that may protect the active ingredient from gastric degradation and enhance its absorption potential. The lipid bilayer mimics human cell membranes, potentially facilitating improved cellular uptake.

Human clinical evidence. A human clinical study demonstrated a 1.52× increase in NAD+ bioavailability with a liposomal formulation compared to standard NAD+. A non-randomized crossover study reported that daily oral supplementation with a liposomal NAD+ preparation significantly increased intracellular NAD+ levels in humans, particularly at the 1,000 mg dose. A randomized, double-blind, crossover clinical trial is currently underway comparing the pharmacokinetics of orally administered native NAD and its liposomal formulation.

Industry validation. The global liposomal supplements market is projected at $771.76 million in 2025 and expected to reach $1.52 billion by 2033, growing at a CAGR of 8.84%. This growth reflects increasing adoption of liposomal delivery across multiple supplement categories.

What this means for procurement: Liposomal delivery is becoming an established approach for optimizing bioavailability. For NAD+ formulations, where bioavailability has historically been a primary limitation, liposomal technology represents an advancement that may support more credible product claims and consumer outcomes.

Beyond bioavailability, several formulation challenges directly impact the commercial viability of liposomal NAD+ products. Procurement teams should evaluate suppliers on their ability to address these technical hurdles.

Oxidation sensitivity. NAD+ is susceptible to oxidative degradation during processing and storage. The phospholipid bilayer in liposomal formulations provides some protection, but the stability of the carrier itself depends on phospholipid quality and antioxidant systems. Suppliers should provide ICH-compliant stability data demonstrating potency retention under accelerated and real-time storage conditions.

Encapsulation loss during processing. Spray-drying and freeze-drying can compromise liposome integrity if process parameters are not carefully controlled. Encapsulation efficiency-the percentage of NAD+ successfully protected within liposomes-varies significantly between suppliers. Procurement teams should request encapsulation efficiency data as part of supplier evaluation.

Phospholipid degradation. The phospholipids forming the liposomal bilayer are themselves susceptible to oxidation. Phospholipid composition (saturated vs. unsaturated), source (sunflower, soy, or marine), and antioxidant systems (e.g., alpha-tocopherol) all affect long-term stability. Request information on phospholipid quality and antioxidant protection.

pH stability. Liposomal formulations can be affected by extreme pH conditions. For beverage applications, formulators should validate liposome stability within the specific pH range of the finished product. Many liposomal NAD+ formulations are optimized for neutral to slightly acidic environments.

What this means for procurement: Suppliers with documented stability data, encapsulation efficiency verification, and phospholipid quality control provide greater formulation reliability. Lab-scale stability does not always translate to commercial production-pilot validation is essential before full-scale manufacturing.

For B2B buyers, the quality of liposomal NAD+ powder is only as reliable as the supplier's technical capability and quality systems. Key evaluation criteria include:

Analytical documentation (non-negotiable): Batch-specific Certificates of Analysis (COA) including HPLC-verified NAD+ content, heavy metal analysis (ICP-MS), microbiological safety data, and residual solvent reports.

Particle size and encapsulation efficiency: Reliable suppliers provide dynamic light scattering (DLS) data showing mean particle size and polydispersity index. Encapsulation efficiency data is essential for verifying formulation integrity.

Stability data: ICH-compliant stability studies (accelerated and real-time) demonstrate whether liposomes maintain their integrity and encapsulation efficiency over the intended shelf life.

Phospholipid quality and source: The oxidative stability of the liposomal carrier itself is critical. Request information on phospholipid composition, source, and antioxidant system.

Certifications and compliance: Manufacturing certifications (cGMP, ISO 22000, FSSC 22000, HACCP) and market-specific certifications (Kosher, Halal, Non-GMO Project Verified) provide assurance of quality management systems and process control.

Supply chain transparency: Documented raw material traceability, batch-to-batch consistency data, and regional warehousing options to support global distribution.

Procurement perspective: Beyond price, procurement decisions should prioritize analytical transparency, formulation consistency, regulatory compliance, and long-term supply reliability to maximize commercial success.

The versatility of liposomal NAD+ powder enables formulation across multiple product categories, each with distinct technical requirements and market positioning opportunities.

Premium longevity supplements. The primary growth driver for liposomal NAD+ remains the premium supplement segment. Longevity is dominating supplement innovation in Europe, with NAD+ inclusion a top strategy for 2026. Brands targeting consumers willing to pay for science-backed efficacy are increasingly adopting liposomal formulations as a point of differentiation.

Functional beverages. Liposomal NAD+ powder offers improved dispersibility compared to raw NAD+, enabling incorporation into beverage systems and powdered formulations.

Healthy aging and cognitive support. As the global population ages, demand for ingredients that support healthy aging and cognitive function continues to rise.

Combination formulations. Increasing interest is being shown in combining NAD+ enhancers with other bioactive agents to produce synergistic effects, including antioxidants such as resveratrol, B vitamins, and mitochondrial support nutrients such as CoQ10.

What this means for procurement: Brands that invest in liposomal NAD+ formulations today position themselves to capture growth across multiple application categories and geographic markets. Suppliers with established liposomal manufacturing capabilities and validated stability data offer the most reliable partnership opportunities.

For B2B procurement managers and product developers, the future of NAD+ supplements is being reshaped by a fundamental shift: from ingredient selection to delivery technology. The NAD+ supplement market is expanding rapidly, with the NAD+ booster market projected to grow at a CAGR of 14.8% through 2032. Human clinical studies have reported that liposomal NAD+ formulations may enhance bioavailability compared to standard NAD+, with a 1.52× increase observed in a clinical study. Consumer demand for science-backed, bioavailability-enhanced products is driving this growth, and liposomal delivery has emerged as a key technology for capturing this opportunity. By partnering with a technically transparent supplier that provides validated analytical documentation, stability data, and regulatory compliance, manufacturers can position their brands at the forefront of the evolving longevity market and capture the growing demand for science-backed NAD+ formulations.

Next Steps for Your Formulation

Most clients begin with a pilot batch (100-500 g) to validate dispersibility, stability, and formulation performance in their specific matrix before scaling to commercial production. Batch-specific COA, particle size data, and stability studies are available to support your product development process.

• [Request bulk liposomal NAD+ samples] – Test our liposomal NAD+ powder grades in your own formulation matrix.
• [Access technical documentation] – Review HPLC assay reports, particle size distribution (DLS), heavy metal analysis, and stability studies.
• [Discuss custom specifications] – Explore custom concentrations, liposomal encapsulation options, or formulation support.
• [Schedule a formulation consultation] – Meet with our R&D team to address NAD+ bioavailability, stability, or application-specific challenges.

MOQ, lead time, and bulk pricing are available upon request. Wellgreen provides batch-specific COA, particle-size analysis, formulation support, and OEM/ODM services for global nutraceutical manufacturers. For technical support, formulation consultation, and bulk quotations, contact our engineering team at liu@wellgreenxa.com.

References

1. Global Info Research. (2026). Global NAD+ Booster Market 2026 by Company, Regions, Type and Application, Forecast to 2032.
2. Research and Markets. (2026). Nicotinamide Adenine Dinucleotide Market Report 2026.
3. Nutrition Business Journal / SupplySide Journal. (2026). NAD+ supplements: Science, market trends, formulation insights.
4. Grand View Research. (2026). Nicotinamide Adenine Dinucleotide Products Market Report 2033.
5. Grand View Research. (2026). Asia Pacific Nicotinamide Adenine Dinucleotide (NAD) Products Market Size & Outlook, 2033.
6. Grand View Research. (2026). The United States Nicotinamide Adenine Dinucleotide (NAD) Products Market Size & Outlook, 2033.
7. MedPath. (2025). A Clinical Study to Compare How Regular NAD+ and a Liposomal NAD+ Formulation Are Absorbed in Healthy Adults.
8. Market Research. (2026). Global Liposomal Supplements Industry Trends Analysis Report 2025, Forecast to 2033.
9. Ingredients Network / Mintel. (2026). Scouting out supplement innovation in 2026: Longevity, women's health, and more.